NATIONWIDE CHILDREN'S
When your child needs a hospital, everything matters.℠

THE OHIO STATE UNIVERSITY
COLLEGE OF MEDICINE

February 15, 2019

Lucia M R Silla, MD, PhD
Professor of Medicine, Department of Hematology, BMT and Cellular Therapy
Universidade Federal do Rio Grande do Sul
Porto Alegre, 90035-903, RS
Office: 55 51 99112587
email: dralucia.silla@gmail.com

Dear Dr. Silla,

I am pleased to collaborate with you in developing NK cell therapies for your patients by providing full access for clinical use of the feeder cell line we developed for this purpose.

As you know, I developed a genetically-modified feeder cell line which generates large numbers of clinical-grade NK cells from normal donors [1-3], patients [4,5], cord blood [6], and embryonic/pluripotent stem cells [7]. We have infused these NK cells into patients in early-Phase clinical trials for hematologic malignancies, solid tumors, and brain tumors, delivering almost 200 infusions to over 80 patients at doses up to $3x10^8$ cells/kg. These studies demonstrated early evidence of efficacy with minimal toxicity [8,9]. Importantly, our long-standing collaboration with you allowed concurrent development of NK cell trials at your institution in Brazil, in which you have also treated around 10 patients with these expanded NK cells.

Unfortunately, the original cell line become entangled in legal issues that restricted our ability to use this valuable resource. In collaboration with the company CytoSen Therapeutics, I recreated the cell line here at Nationwide Children's Hospital. The new cell line, now known as CSTX002, has been fully evaluated for comparability with the original cell line, and we recently treated our first patient with NK cells generated by CSTX002 under approval from the FDA. Importantly, we have retained the right to share this resource with other academic institutions for non-commercial clinical research, and look forward to sharing this with you to continue your important and cutting-edge research in Brazil.

I look forward to continuing our collaboration in NK cell immunotherapy!

Dean Anthony Lee, MD PhD

1. Denman CJ, Senyukov VV, Somanchi SS, et al. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. *PLoS One*. 2012;7(1):e30264.
2. Somanchi SS, Senyukov VV, Denman CJ, Lee DA. Expansion, purification, and functional assessment of human peripheral blood NK cells. *J Vis Exp*. 2011(48).
3. Oyer JL, Pandey V, Igarashi RY, et al. Natural killer cells stimulated with PM21 particles expand and biodistribute in vivo: Clinical implications for cancer treatment. *Cytotherapy*. 2016;18(5):653-663.
4. Fei F, Lim M, George AA, et al. Cytotoxicity of CD56-positive lymphocytes against autologous B-cell precursor acute lymphoblastic leukemia cells. *Leukemia*. 2015;29(4):788-797.
5. Liu Y, Wu HW, Sheard MA, et al. Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy. *Clin Cancer Res*. 2013;19(8):2132-2143.
6. Shah N, Martin-Antonio B, Yang H, et al. Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. *PLoS One*. 2013;8(10):e76781.
7. Knorr DA, Ni Z, Hermanson D, et al. Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy. *Stem Cells Transl Med*. 2013;2(4):274-283.
8. Ciurea SO, Schafer JR, Bassett R, et al. Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation. *Blood*. 2017;130(16):1857-1868.
9. Shah N, Li L, McCarty J, et al. Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. *Br J Haematol*. 2017;177(3):457-466.

Dean Anthony Lee, MD PhD
Professor of Pediatrics and DiMarco Family Endowed Chair in Cell-Based Therapy
Director, Cellular Therapy and Cancer Immunotherapy Program
Department of Hematology, Oncology, and Bone Marrow Transplantation
Nationwide Children's Hospital and The Ohio State University Comprehensive Cancer Center
700 Children's Drive, WA4023, Columbus, OH 43205 | (614)355-3592 | Fax (614) 355-2927 | Dean.Lee@nationwidechildrens.org